Kimberly A Smith

Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

R. Perrone, Kimberly A Smith, A. Thompson, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

CKD as a Model for Improving Chronic Disease Care through Electronic Health Records.

Jenna M. Norton, Kimberly A. Smith, N. Powe, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Innovating and invigorating the clinical trial infrastructure for glomerular diseases.

B. Rovin, M. Jardine, M. Kretzler, 2021, Kidney international.

Change in Estimated GFR and Albuminuria as End Points in Clinical Trials: A Viewpoint From the FDA.

Kimberly A Smith, A. Thompson, John Lawrence, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative.

P. Archdeacon, M. Flessner, Kimberly A Smith, 2016, Journal of the American Society of Nephrology : JASN.

Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.

Mark S Levenson, Kimberly A Smith, A. Thompson, 2016, JAMA internal medicine.

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

R. Falk, D. Faller, S. Dorbala, 2020, Orphanet Journal of Rare Diseases.